Skip to main content
SpringerLink
Log in

Pneumokokkenkonjugatimpfstoffe

Expertenkonsensuspapier zum aktuellen Stand der Dinge

Pneumococcal conjugate vaccine

Consensus on the current situation

  • Konsensuspapiere
  • Published:
Monatsschrift Kinderheilkunde Aims and scope Submit manuscript

Zusammenfassung

Die Wirksamkeit von PCV7, dem ersten zugelassenen Pneumokokkenkonjugatimpfstoff, gegen invasive Pneumokokkeninfektionen wie Sepsis und Meningitis und gegen Pneumonien und akute Otitis media konnte in umfangreichen klinischen Studien und nationalen Impfprogrammen weltweit nachgewiesen werden. Die Inzidenzen von Infektionen durch Streptococcus pneumoniae, die nasopharyngeale Trägerrate und/oder direkte Folgen einer Erkrankung wie Hospitalisierung oder eine Antibiotikabehandlung konnten bei mit PCV7 geimpften Kindern signifikant reduziert werden. Auch die ausgezeichnete Effektivität des generellen Impfprogramms mit PCV7 in Deutschland (seit 2006) und dessen Kosteneffektivität wurden jüngst in der Literatur beschrieben. Ein neuer Pneumokokkenkonjugatimpfstoff, PCV13 mit 6 zusätzlichen Serotypen, wird eine erweiterte Serotypenabdeckung von bis zu 90% bieten. Dieser Impfstoff ist in Chile, Mexiko und Mauritius bereits zugelassen, in Deutschland ist mit einer Verfügbarkeit Ende 2009 zu rechnen. In Anbetracht des breiten Studienprogramms mit exzellenten Ergebnissen, insbesondere bezüglich Sicherheit, Verträglichkeit und Immunogenität, wird ein direkter und problemloser Übergang von PCV7 auf PCV13 möglich sein.

Abstract

Many studies worldwide have demonstrated that PCV7, the first available conjugate vaccine against pneumococci, is very effective in preventing invasive pneumococcal diseases such as septicaemia and meningitis as well as in preventing pneumonia and acute otitis media. The incidence of infections due to Streptococcus pneumoniae, nasopharyngeal carriage of this pathogen, and direct consequences of pneumococcal infection (such as hospitalisation and antibiotic use) have been shown to be reduced in PCV7-vaccinated infants. Recent publications also revealed the efficacy of PCV7 in Germany, its effectiveness following the general vaccination campaign in 2006, and its cost-effectiveness. A new pneumococcal conjugate vaccine based on the established technology of PCV7, designated PCV13 due to an additional six serotypes, will provide an extended serotype coverage of 90%. While this vaccine is already licensed in Chile, Mexico and Mauritius PCV13 will probably be available in Germany at the end of 2009. Based on various studies with excellent results – particularly regarding the safety, tolerability, and immunogenicity of PCV13 – a smooth transition from PCV7 to PCV13 will be possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Adam D, Fehnle K (2008) Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. Vaccine 26:5944–5951

    Article  CAS  PubMed  Google Scholar 

  2. Ansaldi F, Sticchi L, Durando P et al (2008) Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy. J Int Med Res 36:1255–1260

    CAS  PubMed  Google Scholar 

  3. Black S, Shinefield H, Fireman B et al (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19:187–195

    Article  CAS  PubMed  Google Scholar 

  4. Black S, Shinefield H, Baxter R et al (2004) Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 23:485–489

    Article  PubMed  Google Scholar 

  5. CDC (2005) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb Mortal Wkly Rep 54:893–897

    Google Scholar 

  6. CDC (2009) Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine – United States, 1997–2006. MMWR Morb Mortal Wkly Rep 58:1–4

    Google Scholar 

  7. Claes C, Reinert RR, Schulenburg JM von der (2009) Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ 10:25–38

    Article  PubMed  Google Scholar 

  8. Eskola J, Kilpi T, Palmu A et al (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344:403–409

    Article  CAS  PubMed  Google Scholar 

  9. Grijalva CG, Nuorti JP, Arbogast PG et al (2007) Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369:1179–1186

    Article  CAS  PubMed  Google Scholar 

  10. Grimprel E, Laudat F, Baker SA et al (2009) Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccination to healthy children in France. European Society for Paediatric Infectious Diseases (ESPID), Brussels

  11. GSK (2009) Fachinformation Synflorix (Stand: März). GlaxoSmithKline, München

  12. Hsu HE, Shutt KA, Moore MR et al (2009) Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360:244–256

    Article  CAS  PubMed  Google Scholar 

  13. Isaacman D, McIntosh D, Reinert RR (2009) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the seven-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis Aug 21. [Epub ahead of print]

  14. Kieninger DM, Kueper K, Steul K et al (2008) Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given as a 4-dose series with routine vaccines in healty infants and toddlers. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington

  15. Kries R von, Hermann M, Al-Lahham A et al (2002) Will the 7-valent pneumococcal vaccine have a similar impact on all invasive pneumococcal infections in children in Germany as in the Kaiser Permanente Trial? Eur J Pediatr [Suppl 2] 161:S140–S143

    Google Scholar 

  16. Kyaw MH, Lynfield R, Schaffner W et al (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354:1455–1463

    Article  CAS  PubMed  Google Scholar 

  17. Lexau CA, Lynfield R, Danila R et al (2005) Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043–2051

    Article  CAS  PubMed  Google Scholar 

  18. Lloyd A, Patel N, Scott DA et al (2008) Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ 9:7–15

    Article  PubMed  Google Scholar 

  19. Lloyd A, Patel R, Kuchenbecker U et al (2009) The cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) compared to 7-valent pneumococcal conjugate vaccine (PCV7) for childhood vaccination in Germany. European Society for Paediatric Infectious Diseases (ESPID), Brussels

  20. Moore MR (2009) Rethinking replacement and resistance. J Infect Dis 199:771–773

    Article  PubMed  Google Scholar 

  21. Palmu AA, Verho J, Jokinen J et al (2004) The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J 23:732–738

    Article  PubMed  Google Scholar 

  22. Poehling KA, Talbot TR, Griffin MR et al (2006) Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295:1668–1674

    Article  CAS  PubMed  Google Scholar 

  23. Reinert RR (2005) Epidemiologie, Diagnose und Therapie von Infektionskrankheiten. Positionspapier, erstellt unter Federführung des Nationalen Referenzzentrums für Streptokokken (Prof. Dr. med. Ralf René Reinert). Chemotherapie J 14(S23):1–17

    Google Scholar 

  24. Rose M, Zielen S (2009) Impact of infant immunization programmes with pneumococcal conjugate vaccine in Europe. Expert Rev Vaccines 8(10):1351–164

    Article  PubMed  Google Scholar 

  25. Rueckinger S, Van der Linden M, Reinert RR et al (2009) Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27:4136–4141

    Article  Google Scholar 

  26. Strutton DR, Kuchenbecker U, Hwang S et al (2009) Impact of 13-valent pneumococcal conjugate vaccination on costs and outcomes in Germany and the United States. European Society for Paediatric Infectious Diseases (ESPID), Brussels

  27. Van der Linden M, Reinert RR (2008) Surveillance of IPD in children in Germany 2004–2008, before and after the introduction of the national immunization program for PCV7. International Symposium on Pneumococci & Pneumococcal Diseses (ISPPD), Reykjavik

  28. Van der Linden M, Imoehl M, Kries R von et al (2009) Epidemiologie invasiver Pneumokokkenerkrankungen bei Kindern in Deutschland von 1997–2009, Effekte der Einführung der Pneumokokken Konjugatimpfung. 1. Nationale Impfkonferenz, Mainz

  29. Van der Linden M, Imoehl M, Kries R von et al (2009) National immunization program for Prevenar (PCV7) results in reduction of incidence of IPD in german children. European Society for Paediatric Infectious Diseases (ESPID), Brussels

  30. Van der Linden M, Reinert RR, Imoehl M (2009) Invasive Pneumokokken-Erkrankungen bei Erwachsenen in Deutschland; Mögliche Herdenimmunitätseffekte nach Einführung der Pneumokokken-Konjugatimpfung bei Kindern. 1. Nationale Impfkonferenz, Mainz

  31. Vesikari T, Wysocki J, Chevallier B et al (2009) Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 28:S66–S76

    Article  PubMed  Google Scholar 

  32. Vestrheim DF, Lovoll O, Aaberge IS et al (2008) Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26:3277–3281

    Article  CAS  PubMed  Google Scholar 

  33. Whitney CG, Pilishvili T, Farley MM et al (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368:1495–1502

    Article  CAS  PubMed  Google Scholar 

  34. Zhou F, Shefer A, Kong Y et al (2008) Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. Pediatrics 121:253–260

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Beratungstätigkeit für Firma Wyeth

Author information

Authors and Affiliations

  1. München, Gabriel-Max-Straße 43, 81545, München, Deutschland

    D. Adam

  2. Kinder- und Jugendarztpraxis , Tegernsee, Deutschland

    A. Busse

Authors
  1. D. Adam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Busse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Adam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adam, D., Busse, A. Pneumokokkenkonjugatimpfstoffe. Monatsschr Kinderheilkd 157, 1252–1256 (2009). https://doi.org/10.1007/s00112-009-2132-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00112-009-2132-5

Schlüsselwörter

Keywords

Search

Navigation